What is Aktis Oncology, Inc.'s (AKTS) StockRank?

MoatMap's StockRank for Aktis Oncology, Inc. (AKTS) is 9/100, with a Strong Sell signal. This is a composite score combining Quality (33), Value (38), and Momentum (22) factor ranks across MoatMap's 19,000+ stock universe.

Does Aktis Oncology, Inc. have an economic moat?

Aktis Oncology, Inc. (AKTS) has a Quality factor score of 33/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Aktis Oncology, Inc. a buy, hold, or sell?

MoatMap's current signal for Aktis Oncology, Inc. (AKTS) is Strong Sell, based on a StockRank of 9/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Aktis Oncology, Inc. in?

Aktis Oncology, Inc. (AKTS) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

AKTS

STRONG SELLREMOVE

Aktis Oncology, Inc. · Healthcare · United States · $1.1B · Avg Vol: $4M/d

StockRank

P/E (TTM)

—

ROE

—

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

An early-stage radiopharmaceutical biotech company that, while operating in an exciting field, is highly speculative, pre-revenue, and does not fit our quality compounder criteria.

COMPANY DESCRIPTION

Aktis Oncology, Inc. is a biotechnology company developing novel radiopharmaceutical therapeutics for the treatment of solid tumors. It focuses on creating targeted alpha-emitting radiopharmaceuticals with improved tumor penetration and systemic distribution, aiming for superior efficacy in oncology. The company is a clinical-stage biotech innovator in the emerging radiopharmaceutical space, seeking to revolutionize cancer treatment through precision medicine.

FINANCIAL SUMMARY

Year	2022	2023	2024	CAGR
Revenue	0	0	1M	—
EPS	—	—	—	—
Shares	—	—	—	—
Debt	2M	13M	12M	160.1%
Equity	-19M	-46M	-88M	—
Op CF	-18M	-30M	15M	—
Inv CF	-2M	-69M	-190M	—
Fin CF	120M	0	183M	—

PRICE (1M)+12.9%

SMA 50SMA 200

$21.93

RSI (14)

57.9

SCORE BREAKDOWN

Quality

ROIC

-32.0%21.3

ROE

—N/A

GP/Assets

-23.9%4.3

Op. Margin

-703.6%8.7

FCF/Assets

—N/A

Piotroski

—7.2

Int. Cover

—N/A

D/E Ratio

0.02x81.6

Current Ratio

19.49x95.3

Value

P/E (TTM)

—N/A

EV/EBITDA

-8.9x80.2

P/FCF

—N/A

P/B

2.4x48.3

P/S

146.5x6.2

Div Yield

—N/A

Momentum

52W High %

—N/A

RS 6M

—N/A

SMA 50/200

—N/A

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

-65%7.1

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$1.1B

P/E (Forward)

-11.0x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AKTS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
AKTS	Aktis Oncology, Inc.(you)	$1.1B	9	STRONG SELL
OLMA	Olema Pharmaceuticals, Inc.	$1.1B	9	STRONG SELL
EYPT	EyePoint, Inc.	$1.1B	8	STRONG SELL
AVLN	Avalyn Pharma Inc.	$1.3B	8	STRONG SELL
SPRY	ARS Pharmaceuticals, Inc.	$933M	10	STRONG SELL
COAG	Hemab Therapeutics Holdings, Inc.	$1.3B	12	STRONG SELL
ZBIO	Zenas BioPharma, Inc.	$1.2B	4	STRONG SELL
MAZE	Maze Therapeutics, Inc.	$1.5B	6	STRONG SELL
SANA	Sana Biotechnology, Inc.	$871M	4	STRONG SELL
RXRX	Recursion Pharmaceuticals, Inc.	$1.8B	9	STRONG SELL

Peer medians: ROE -22.4% · P/E 25.1x · Gross margin 44.3%

Aktis Oncology, Inc. (AKTS) — Stock Score Summary

Aktis Oncology, Inc. (AKTS) has a MoatMap StockRank of 9/100 based on Quality (33/100), Value (38/100), and Momentum (22/100) factor scores. The current signal is STRONG SELL. An early-stage radiopharmaceutical biotech company that, while operating in an exciting field, is highly speculative, pre-revenue, and does not fit our quality compounder criteria.

Key Financial Metrics

Price	$21.93
Market Cap	$1.1B
P/E (Forward)	-11.02
Price/Book	2.40
Return on Invested Capital	-32.0%
Debt/Equity	2.29
Gross Margin	0.0%
Operating Margin	-703.6%
Revenue Growth	123.0%

Aktis Oncology, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Aktis Oncology, Inc.’s (AKTS) StockRank?: MoatMap’s StockRank for Aktis Oncology, Inc. (AKTS) is 9/100, with a Strong Sell signal. It is a composite of Quality (33), Value (38), and Momentum (22) factor ranks across MoatMap’s 19,000+ stock universe.
Does Aktis Oncology, Inc. have an economic moat?: Aktis Oncology, Inc. (AKTS) has a Quality factor score of 33/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Aktis Oncology, Inc. a buy, hold, or sell?: MoatMap’s current signal for Aktis Oncology, Inc. (AKTS) is Strong Sell, based on a StockRank of 9/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Aktis Oncology, Inc. in?: Aktis Oncology, Inc. (AKTS) operates in the Healthcare sector, specifically the Biotechnology industry (United States).